Furthermore, studies involving MC38 and other tumor models have revealed that therapeutic strategies targeting TIGIT—including monoclonal antibody blockade, gene knockout, and combination therapies—possess significant therapeutic potential [192,198,209]. Here, TIGIT is linked to neoplasm.